The landscape of myeloid neoplasms with isochromosome 17q discloses a specific mutation profile and is characterized by an accumulation of prognostically adverse molecular markers

Article metrics


Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1
Figure 2


  1. 1

    Fioretos T, Strombeck B, Sandberg T, Johansson B, Billstrom R, Borg A et al. Isochromosome 17q in blast crisis of chronic myeloid leukemia and in other hematologic malignancies is the result of clustered breakpoints in 17p11 and is not associated with coding TP53 mutations. Blood 1999; 94: 225–232.

  2. 2

    McClure RF, Dewald GW, Hoyer JD, Hanson CA . Isolated isochromosome 17q: a distinct type of mixed myeloproliferative disorder/myelodysplastic syndrome with an aggressive clinical course. Br J Haematol 1999; 106: 445–454.

  3. 3

    Mertens F, Johansson B, Mitelman F . Isochromosomes in neoplasia. Genes Chromosomes Cancer 1994; 10: 221–230.

  4. 4

    Kanagal-Shamanna R, Bueso-Ramos CE, Barkoh B, Lu G, Wang S, Garcia-Manero G et al. Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53. Cancer 2012; 118: 2879–2888.

  5. 5

    Pinheiro RF, Chauffaille ML, Silva MR . Isochromosome 17q in MDS: a marker of a distinct entity. Cancer Genet Cytogenet 2006; 166: 189–190.

  6. 6

    Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th ed. International Agency for Research on Cancer (IARC): Lyon, 2008.

  7. 7

    Gelsi-Boyer V, Trouplin V, Adelaide J, Bonansea J, Cervera N, Carbuccia N et al. Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia. Br J Haematol 2009; 145: 788–800.

  8. 8

    Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature 2011; 478: 64–69.

  9. 9

    Meggendorfer M, Roller A, Haferlach T, Eder C, Dicker F, Grossmann V et al. SRSF2 mutations in 275 cases with chronic myelomonocytic leukemia (CMML). Blood 2012; 120: 3080–3088.

  10. 10

    Piazza R, Valletta S, Winkelmann N, Redaelli S, Spinelli R, Pirola A et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet 2013; 45: 18–24.

  11. 11

    Meggendorfer M, Bacher U, Alpermann T, Haferlach C, Kern W, Gambacorti-Passerini C et al. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations. Leukemia 2013; 27: 1852–1860.

  12. 12

    Bejar R . Clinical and genetic predictors of prognosis in myelodysplastic syndromes. Haematologica 2014; 99: 956–964.

  13. 13

    Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013; 27: 1861–1869.

  14. 14

    Itzykson R, Kosmider O, Renneville A, Gelsi-Boyer V, Meggendorfer M, Morabito M et al. Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol 2013; 31: 2428–2436.

  15. 15

    Visconte V, Tabarroki A, Zhang L, Hasrouni E, Gerace C, Frum R et al. Clinicopathologic and molecular characterization of myeloid neoplasms harboring isochromosome 17(q10). Am J Hematol 2014; 89: 862.

Download references


We thank all clinicians for sending samples to our laboratory for diagnostic purposes and for providing clinical information and follow-up data. In addition, we would like to thank all the co-workers at the MLL Munich Leukemia Laboratory for approaching together many aspects in the field of leukemia diagnostics and research.

Author contributions

MM investigated molecular mutations, analyzed the data and wrote the manuscript; CH was responsible for cytogenetics; WK was involved in statistical analyses; MZ performed array CGH; KM characterized morphological findings; TH was responsible for cytomorphologic analysis and was involved in the collection of clinical data as well as manuscript preparation. All authors read and contributed to the final version of the manuscript.

Author information

Correspondence to M Meggendorfer.

Ethics declarations

Competing interests

CH, WK and TH declare equity ownership of MLL Munich Leukemia Laboratory. MM, MZ and KM are employed by MLL Munich Leukemia Laboratory.

Additional information

Supplementary Information accompanies this paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Further reading